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Abstract
Background: Adolescents have been identified as a high-risk group for poor adherence to and defaulting from combination
antiretroviral therapy (cART) care. However, data on outcomes for adolescents on cART in resource-limited settings remain
scarce.
Methods: We developed an observational study of patients who started cART at The AIDS Service Organization (TASO) in
Uganda between 2004 and 2009. Age was stratified into three groups: children (#10 years), adolescents (11–19 years), and
adults ($20 years). Kaplan-Meier survival curves were generated to describe time to mortality and loss to follow-up, and Cox
regression used to model associations between age and mortality and loss to follow-up. To address loss to follow up, we
applied a weighted analysis that assumes 50% of lost patients had died.
Findings: A total of 23,367 patients were included in this analysis, including 810 (3.5%) children, 575 (2.5%) adolescents, and
21 982 (94.0%) adults. A lower percentage of children (5.4%) died during their cART treatment compared to adolescents
(8.5%) and adults (10%). After adjusting for confounding, other features predicted mortality than age alone. Mortality was
higher among males (p,0.001), patients with a low initial CD4 cell count (p,0.001), patients with advanced WHO clinical
disease stage (p,0.001), and shorter duration of time receiving cART (p,0.001). The crude mortality rate was lower for
children (22.8 per 1000 person-years; 95% CI: 16.1, 29.5), than adolescents (36.5 per 1000 person-years; 95% CI: 26.3, 46.8)
and adults (37.5 per 1000 person-years; 95% CI: 35.9, 39.1).
Interpretation: This study is the largest assessment of adolescents receiving cART in Africa. Adolescents did not have cART
mortality outcomes different from adults or children.
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Introduction
Programmatic evaluations of HIV/AIDS in resource-limited
settings have historically focused on adult and child populations
[1,2] There is growing appreciation, however, that other age
groups pose a particular challenge to the provision of combination
antiretroviral therapy (cART). For instance, the number adoles-
cents on cART continues to increase [3]. This is largely a
reflection of successful treatment of perinatally-infected children,
infections during early adolescence, and the expansion of access to
cART worldwide [3] Globally, in 2008, over 40% of all new
reported HIV infections occurred in young people ages 15–24 [4].
A 2009 study from Southern Africa, Ferrand et al predicts a
substantial epidemic among perinatally-infected adolescents de-
spite previous assertions that few of these children would reach
adolescence [5]. As these children mature and enter adolescence, it
is important that appropriate services are available to counsel
youth about sexual safety, adherence to ART and reproductive
choices in order to prevent further horizontal transmission.
Adolescence can be a confusing time for youth, especially those
living with a chronic and often stigmatized disease. A number of
challenges have been identified that may compromise positive
outcomes of care for adolescents. They may be particularly
rebellious, may not have caregivers unlike younger children, and
there many be challenges associated with puberty and disease [6].
The few published studies examining outcomes of care among
adolescents on cART report that cART access and adherence is
lower in adolescents than in adults [7–12]. Nachega and
colleagues published the only study reporting adolescent clinical
outcomes in Africa.13 In this relatively small sample, (n = 154), the
authors reported significantly worse virological suppression in
adolescents versus adults in a cohort of patients from nine southern
African countries receiving privately purchased cart [13]. No
specific data on reasons of non-adherence were documented in
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that study and authors speculated on possible factors of non-
adherence to cART and social (stigma/discrimination; social
support) or structural (cost, access to care) issues in their privately
managed AIDS Care pilot study population [13].
Not all settings in Africa are alike, neither can we expect that
outcomes in a privately purchased cART program will be similar
to a publicly funded one. This study compares survival and loss to
follow-up of adolescents to children and adults using a large
dataset from a nationally representative cohort of HIV patients
receiving free cART in Uganda.
Methods
Ethics statement
This study received ethical approval from TASO Administra-
tive Research Board, a Uganda National Science and Technology
Council approved board, and from University of British
Columbia. Informed consent was not required as this was
routinely collected operational data and the institutional review
boards waived the need for consent.
Programme
The AIDS Support Organization (TASO) is the largest and
oldest national non-governmental AIDS service organization in
Africa. Founded in 1987, TASO currently provides psychosocial
support, clinical care, and cART free of charge to people with HIV
in Uganda. TASO started prescribing cART in 2004 and now
provides treatment to approximately 24 000 patients throughout 11
clinical sites in Uganda. Criteria used for initiation of cART include
World Health Organization (WHO) clinical disease stage III or IV
or a CD4 cell count below 250 cells/mm3 [14]. Patients starting
cART typically receive an initiation regimen of non-nucleoside
reverse transcriptase inhibitor with first-line treatment comprising
nevirapine, lamivudine and stavudine and boosted lopinavir,
didanosine and zidovudine as second-line [15,16].
Data Collection
This study is based on data collected routinely for clinical
monitoring and evaluation purposes at TASO. Clinicians
complete standardized patient forms detailing patient demograph-
ics, clinical, psychosocial, and drug utilization data at each patient
visit. These data are then entered into the TASO data collection
database at each site by trained data capturers. All data are
anonymized using a unique, confidential identification number.
Clinic staff, nurses and clinical officers or physicians offer
adherence monitoring and clinical support. For community-based
recipients of care, a field monitoring team equipped with
motorcycles is responsible for patient adherence, social support,
and follow-up. This team, which includes medical attendants who
conduct HIV testing, adherence counselling, clinical observation,
and provide cART to patients, visits patients who fail to show for
any appointment for three months or longer and patients who
have requested home-based care.
The present study includes all patients who initiated cART since
the start of the programme (2004), irrespective of age. For each
patient, the following baseline information was recorded: age at
start of cART (years), gender (male, female), exact baseline CD4
cell count, WHO clinical disease stage, loss to follow-up status,
date last seen for care, and where applicable, date of death.
Table 1. Characteristics of study participants by age group.
Variable
Child
(#10 years)
Adolescent
(11–19 years)
Adult
($20 years) p-value
Gender
Female 411 (50.7%) 361 (62.8%) 15,259 (69.4%) ,0.001
Male 399 (49.3%) 214 (37.2%) 6,723 (30.6%)
CD4 cell count (cells/mm3)
,50 105 (16.1%) 121 (26.4%) 3,364 (18.5%) ,0.001
50–99 75 (11.5%) 69 (15%) 2,900 (15.9%)
100–199 99 (15.2%) 137 (29.8%) 6,926 (38.0%)
200–299 107 (16.4%) 64 (13.9%) 2,985 (16.4%)
$300 267 (40.9%) 68 (14.8%) 2,047 (11.2%)
WHO Stage
Stage I 7 (1.3%) 11 (2.9%) 459 (3.2%) 0.192
Stage II 301 (56.3%) 218 (58.4%) 7,861 (54.5%)
Stage III 179 (33.5%) 115 (30.8%) 4,908 (34.0%)
Stage IV 48 (9.0%) 29 (7.8%) 1,201 (8.3%)
Death
No 773 (95.4%) 536 (93.2%) 20,510 (93.3%) 0.057
Yes 37 (4.6%) 39 (6.8%) 1,472 (6.7%)
Lost to follow-up
No 771 (95.2%) 533 (92.7%) 20,573 (93.6%) 0.124
Yes 39 (4.8%) 42 (7.3%) 1,409 (6.4%)
Year of first therapy
Median (IQR) 2007 (2006–2008) 2007 (2006–2008) 2007 (2005–2007) ,0.001
doi:10.1371/journal.pone.0019261.t001
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Data Analysis
The cohort was stratified into three age groups: children (age #10
years), adolescents (age 11–19 years), and adults (age$20 years). These
age definitions have been used before by Nachega et al. [13]. Baseline
characteristics between age groups were assessed for skew and
compared using analysis of variance. We used Weibull hazards to
model the associations between age and risk of mortality and loss to
follow-up, including gender and baseline CD4 cell count as potential
confounders [17]. Hazard proportionality was assessed by analysis of
scaled Schoenfeld residuals. Kaplan-Meier survival curves were
generated to describe time to mortality and loss to follow-up for the
three age groups, with survival curves compared using the log-rank test.
Survival times were expressed in months. We assessed the potential
misclassification of mortality among those lost to follow-up by assuming
that 50% of the patients lost to follow-up had died. We weighted this
assumption according to individuals with lower baseline CD4 status
using a random sequence generator. This figure of 50% mortality
among defaulters is consistent with evaluations examining the extent of
attrition associated with mortality [18]. All significance tests were two-
sided with a p-value of,0.05 considered significant. All analyses were
conducted using SAS version 8 (SAS Institute, Cary, NC).
Results
A total of 23,367 patients were included in this analysis. There
were 810 (3.5%) children, 575 (2.5%) adolescents, and 21,982
(94.0%) adults at baseline. Follow-up time differed between the age
groups. Adults were followed for a median of 32 months (IQR: 19,
45), and children and adolescents were followed for 28 months
(IQR: 18, 38) and 28 months (IQR: 17, 38), respectively (p,0.001).
Table 1 shows the demographic and clinical characteristics of
patients by age group. The majority of patients overall were
female, and there was a significantly higher proportion of females
than males in the adolescent and adult age groups (p,0.001).
Baseline CD4 at the time of cART initiation was significantly
different across the age groups (p,0.001): child patients started
cART at a median CD4 count of 238 cells/ml (IQR: 91, 490),
adolescent patients started at a median of 131 cells/ml, (IQR: 46,
213) and adult patients started at a median of 142 cells/ml (IQR:
71, 206). A lower percentage of children (5.4%) died during their
cART treatment compared to adolescents (8.5%) and adults
(10%). There were also no significant differences in WHO clinical
disease stage and loss to follow-up between the 3 age groups.
Figure 1. Kaplan-Meier product limit estimates for the probability of survival.
doi:10.1371/journal.pone.0019261.g001
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Table 2. Multivariate analysis of risk of death.
Variable
Unadjusted
(95% confidence interval) p-value
Adjusted
(95% confidence interval) p-value
Age group
Adolescent (11–19 years) 1.00 1.00
Child (#10 years) 0.63 (0.42,0.94) 0.025 0.74 (0.47,1.14) 0.174
Adult ($20 years) 1.10 (0.83,1.46) 0.501 1.07 (0.78,1.46) 0.683
Gender
Male versus Female 1.50 (1.38,1.63) ,0.001 1.41 (1.29,1.55) ,0.001
CD4 cell count (cells/mm3)
,50 1.00 1.00
50–99 0.60 (0.53,0.68) ,0.001 0.60 (0.52,0.68) ,0.001
100–199 0.40 (0.36,0.45) ,0.001 0.41 (0.36,0.45) ,0.001
200–299 0.32 (0.27,0.38) ,0.001 0.35 (0.30,0.42) ,0.001
$300 0.28 (0.23,0.34) ,0.001 0.33 (0.27,0.41) ,0.001
WHO Stage
Stage I or II 1.00
Stage III 1.87 (1.67,2.10) ,0.001
Stage IV 3.64 (3.14,4.23) ,0.001
Year of first therapy
Per 1 year increase 0.82 (0.80,0.85) ,0.001 0.85 (0.82,0.89) ,0.001
Note: 50% of those lost to follow-up were assumed dead.
doi:10.1371/journal.pone.0019261.t002
Figure 2. Kaplan-Meier product limit estimates for time to loss to follow-up.
doi:10.1371/journal.pone.0019261.g002
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Overall, mortality was higher among males (p,0.001), patients
with a CD4 cell count lower than 100 cells/mm3 at cART
initiation (p,0.001), patients with a WHO clinical disease stage of
III or IV at cART initiation (p,0.001), and patients who started
cART at an earlier time point (p,0.001). The crude mortality rate
was lower for children (22.8 per 1000 person-years; 95% CI: 16.1,
29.5), than adolescents (36.5 per 1000 person-years; 95% CI: 26.3,
46.8) and adults (37.5 per 1000 person-years; 95% CI: 35.9, 39.1).
Figure 1 shows the Kaplan-Meier curve for time to mortality. At
12 months, the probability of survival was 0.956 (95% CI: 0.942,
0.971) for children, 0.933 (95% CI: 0.912, 0.954) for adolescents,
and 0.923 (95% CI: 0.920, 0.927) for adults. By 48 months, this was
0.943 (95% CI: 0.926, 0.960) for children, 0.905 (95% CI: 0.879,
0.931) for adolescents, and 0.891 (95% CI: 0.886, 0.895) for adults.
The p-value of the log-rank test was ,0.001, suggesting an initial
difference in the survival distributions between the age groups.
Table 2 summarizes the unadjusted and adjustedWeibull hazards
model for mortality. After adjusting for gender, baseline CD4 cell
count, and year of therapy initiation, there was no difference
between adolescents and children (aHR: 0.74; 95%CI: 0.47, 1.14) or
adolescents and adults (aHR: 1.07; 95% CI: 0.78, 1.46).
Figure 2 displays the Kaplan-Meier curve for the sensitivity
analysis of time to loss to follow-up. The p-value of the log-rank
test was 0.134, suggesting there is no difference in the distributions
of age for loss to follow-up.
Discussion
This study is the largest assessment of clinical outcomes among
adolescents receiving cART in Africa. In this study, crude
adolescent mortality was significantly different from child patients,
yet, loss to follow-up was not. After adjusting for explanatory
variables, we did not demonstrate a significance difference in
either mortality or loss to follow up across groups.
The recent report from southern Africa by Nachega et al. found
that adolescents have worse outcomes compared to their adult
counterparts in terms of virologic suppression and adherence [13],
but did not explore survival. Nachega and colleagues examined
adherence to cART as a possible predictor of virological suppression
in adolescents compared to adults receiving cART from a private
provider managed AIDS care programme in Southern Africa and
found an increased rate of virological failure among adolescents
when compared to adults (Hazard Ratio 3.03, 95% CI: 1.31–3.13)
[13]. Possible explanations for increased virological failure in
adolescents include poorer pharmacy refill adherence than adults
and lack of social support. It is likely that outcomes such as mortality
and adherence are influenced by region and programme level factors
(e.g. private versus public sector), which merit further research.
As most adolescents would be infected at birth, many individuals
would have died before achieving adolescence. As the number of
adolescents enrolled in treatment grows and patient live longer, the
question of adherence and retention will become increasingly
important for health care practitioners. Often adolescents fall
through the cracks between pediatric care and adult care.
Specialized adolescent health care clinics providing counseling,
testing, and treatment have been developed in countries like South
Africa to meet the needs of HIV-positive and at-risk youth [19].
As with almost all assessments of mortality in African cohorts,
we found that male gender was independently predictive of
mortality. This finding is inconsistent with advocacy for increased
attention to female issues and we hope that the medical and
advocacy communities can promote an evidence-based strategy to
responding to local epidemics. In our experience, and others, male
patients are typically late to receive cART, have more advanced
illness, and have worse clinical outcomes [20].
As with any study of this nature, there were several limitations.
Loss to follow-up may have led to a misclassification of mortality as
loss to follow up. TASO uses active retention strategies to locate
patients who do not attend their scheduled appointments, thus
reducing degree of lost to follow-up. We also attempted to
overcome the issue of loss to follow-up in the present study with
the use of our assumption that 50% of those lost had died 50%
[18]. Although it was not possible to include the primary causes of
death in this study. It is likely that the primary causes of death for
adolescent patients differ than other age groups.
It should also be noted that CD4 cell count data at cART
initiation, was not complete. The lack of complete CD4 cell counts
is a reflection of the diverse settings in which TASO works in
Uganda. This problem is also common in other resource-
constrained settings [21]. Additionally, routine patient data on
HIV viral load or antiretroviral resistance testing is not available in
our setting. Therefore, we cannot be sure of the number of
treatment failures and determinants. Finally, since this is an
observational study, no conclusions about causality can be made.
As in all observational cohort studies, unmeasured differences may
exist among in the population under study.
Strengths of the study include the large sample size and long-
term follow-up. The cohort includes patients receiving care
throughout Uganda, and thus captures a wide range of differing
patient experiences based on regional variation. Furthermore, the
use of active retention to reduce loss to follow-up has resulted in
higher patient retention rates than similar cohort studies.
In conclusion, our study confirms earlier assertions that
providing cART to adolescent patients is a complex undertaking.
Adolescents have been overlooked in the literature and also in
programming. They have unique needs that require tailored
services and targeted research. As this population becomes
increasingly important in the epidemic, further investigation into
the causes of loss to follow up and mortality are needed for this
subgroup of patients in order to design and evaluate supportive
strategies for this vulnerable population.
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